Preview

Онкоурология

Расширенный поиск

Роль гормонотерапии у больных локализованным и местно-распространенным раком предстательной железы при использовании радикальных методов лечения

https://doi.org/10.17650/1726-9776-2005-1-2-54-58

Полный текст:

Об авторах

В. Б. Матвеев
ГУ РОНЦ им. Н.Н. Блохина РАМН
Россия


М. И. Волкова
ГУ РОНЦ им. Н.Н. Блохина РАМН
Россия


Список литературы

1. Давыдов М.И., Аксель Е.М. Злокачественные новообразования в России и странах СНГ в 2002 г. — М., 2004. — С. 110—167.

2. Prayer-Galetti T., Zattoni F., Capizzi A. et al. Disease free survival in patients with pathological C stage prostate cancer at radical reropubic prostatectomy submitted to adjuvant hormonal treatment //Eur.Urol. — 2000. — V. 38. — Аbstr. 48.

3. Messing E.M., Manola J., Sarosdy M. et al. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer //N.Engl.J.Med. — 1999. — V. 341, № 9. — Р. 1781—1788.

4. Soloway M.S., Sharifi R., Wajsman Z. et al. Randomized prospective study comparing radical prostatectomy alone versus radical prostatectomy preceded by androgen blockade in clinical stage B2 (T2bNxM0) prostate cancer // J. Urol. — 1995. — V. 154. — Р. 424—428.

5. Goldenberg S.L., Klotz L.H., Jewett M.A.S. et al. Randomized controlled study of neoadjuvant reversible androgen withdrawal therapy with cyproteron acetate in the surgical management of localized prostate cancer // J. Urol. — 1995. — V. 153. — Аbstr. 254A.

6. Van Poppel H., Ridder D.D., Elgamal A.A. et al. Neoadjuvant hormonal therapy before radical prostatectomy decreases the number of positive surgical margins in stage T2 prostate cancer: interim results of a prospective randomized study // J. Urol. — 1995. — V. 154. — P. 429—434.

7. Pollack A., Zagars G.K., Smith L.G. et al. Preliminary results of a randomized dose-escalation study camparing 70 Gy to 78 Gy for the treatment of prostate cancer // Int. J. Radiat. Oncol. Biol. Phys. — 1999. — V. 45. — P. 146.

8. Zelefsky M.J., Leibel S.A., Gaudin P.B. et al. Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer // Int. J. Radiat. Oncol. Biol. Phys. — 1998. — V. 41. — P. 491—500.

9. Bolla M., Collette L., Blank L. еt al. Long-trem results with immediate androgen supression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomized trial // Lancet. — 2002. — V. 360, № 13. — P. 103—108.

10. Pilepich M., Winter K., Lawton C.A. et al. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinomalong-term results of phase III RTOG 85— 31 // Int. J. Radiat. Oncol. Biol. Phys. — 2005. — V. 61(5). — P. 1285—1290.

11. Granfors T., Modig H., Damber J.-E. et al. Combined orchiectomy and external radiotherapy versus radiotherapy alone for nonmetastatic prostate cancer with or without pelvic lymph node involvement: a prospective randomized study // J. Urol. — 1998. — V. 159(6). — P. 2030—2034.

12. Shipley W., Lu J.D., Pilepich M.V. et al. Effect of a short course of neoadjuvant hormonal therapy on the response to subsequent androgen suppression in prostate cancer patients with relapse after radiotherapy: a secondary analysis of the randomized protocol RTOG 86—10 // Int. J. Radiat. Oncol. Biol. Phys. — 2002. — V. 54 (5). — P. 1302—1310.

13. Hanks G.E., Pajak T.F., Porter A. et al. Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92—02 // J. Clin. Oncol. — 2003. — V. 21 (21). — P. 3972—3978.

14. Holzbeierlein J.M., McLaughlin M.D., Thrasher J.B. Complications of androgen deprivation therapy for prostate cancer //Curr. Opin. Urol. — 2004. — V. 14 (3). — P. 177—183.

15. D’Amico A.V., Manola J., Loffredo M. et al. 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial // JAMA. — 2004. — V. 292 (7). — P. 821—827.

16. Hanks G.E., Buzydlowski J., Sause W.T. et al. Ten-year outcomes for pathologic node-positive patients treated in RTOG 75—06. // Int. J. Radiat. Oncol. Biol. Phys. — 1998. — V. 40 (4). — P. 765—768.

17. Lawton C.A., Winter K., Byhardt R. et al. Androgen suppression plus radiation versus radiation alone for patients with D1 (pN+) adenocarcinoma of the prostate (results based on a national prospective randomized trial, RTOG 85-31). Radiation Therapy Oncology Group // Int. J. Radiat. Oncol. Biol. Phys. — 1997. — V. 38 (5). — P. 931—939.


Для цитирования:


Матвеев В.Б., Волкова М.И. Роль гормонотерапии у больных локализованным и местно-распространенным раком предстательной железы при использовании радикальных методов лечения. Онкоурология. 2005;1(2):54-58. https://doi.org/10.17650/1726-9776-2005-1-2-54-58

For citation:


., . . Cancer Urology. 2005;1(2):54-58. (In Russ.) https://doi.org/10.17650/1726-9776-2005-1-2-54-58

Просмотров: 6


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1726-9776 (Print)
ISSN 1996-1812 (Online)
X